Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...

Axsome Therapeutics (NASDAQ:AXSM) stock rallied 15% in morning trading on news it has settled patent litigation with Teva (NYSE:TEVA) over its antidepressant drug Auvelity. Axsome (NASDAQ ...

Axsome will grant Teva a license to sell its generic version of Auvelity beginning on or after March 31, 2039, if pediatric exclusivity is granted, or on or after Sept. 30, 2038, if no pediatric ...

Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

The year-over-year increase in revenues can be attributed to strong sales of Auvelity (AXS-05). In the past year, shares of Axsome have rallied 41.3% against the industry’s decline of 8.8%.

Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $132 and keeps an Outperform rating on the shares. The firm ...

Axsome Therapeutics' Q4 revenue surged to $118.77 million, surpassing expectations with significant growth in Auvelity sales. Axsome reports progress on multiple drug applications, including ...

The quarter was marked by strong sales from its commercial products, Auvelity and Sunosi, and heightened strategic investment in research and development (R&D) reflected in increased spending.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year growth. Auvelity ® 4Q and full year 20 ...